Phenomic AI applies advanced AI/ML tools to screen complex, multi-cell systems at scale to reveal novel drug targets that emerge from cell–cell interactions. The company focuses on discovering antibody drug targets for challenging diseases, notably cancer and fibrosis. Its platform is used to identify targets to be advanced internally or with partners. Phenomic AI launched with seed financing to advance its pipeline and support preclinical development. The company will use the proceeds to support preclinical studies for two validated cancer drug targets and to discover and advance additional targets. Leadership includes CEO Sam Cooper, newly appointed CSO Dr. Michael Briskin, and an SAB featuring Nobel Laureate James P. Allison and Padmanee Sharma; the company is based in Toronto and also has offices in Boston.

Total raised

$6M

Funding rounds

1

Latest round

Seed

Latest activity

Oct 2020